Heparin sodium injection is an antithrombotic agent that contains heparin
sodium (low molecular weight heparin sodium) as well as inactive ingredients
such as sodium chloride or water for injection. Below reach heparin sodium
manufacturer Kowloon medicine for you to introduce in detail a down heparin
sodium injection usage dosage
1. Treatment of acute deep vein thrombosis. Heparin sodium can be injected subcutaneously once or twice daily. Daily usage: 200IU/kg body weight, hypodermic injection daily, no need to monitor the anticoagulant effect. The daily amount should not exceed 18000IU. Two times daily usage: 100IU/kg body weight, hypodermic injection twice daily, this dose is suitable for patients with high risk of bleeding. Monitoring is usually not required during treatment, but functional antibody-XA can be determined. The maximum blood concentration can be measured by blood calibration 3-4 hours after subcutaneous injection. The recommended blood concentration range is 0.5-1.0IU anti-xa/mL. The administration of heparin sodium is accompanied by immediate oral administration of a vitamin K antagonist. Heparin therapy should be continued until the prothrombin complex level (factor II.VIi.ix.X) is reduced to the therapeutic level. Usually the combination therapy takes at least five days. Prevent clotting during hemodialysis and hemofiltration.
2. Chronic renal failure, patients with no known risk of bleeding: hemodialysis and hemofiltration for no more than 4 hours: the dose is as follows or intravenous rapid injection of 5000IU. Hemodialysis and hemofiltration for more than 4 hours: 30-40IU/kg body weight by intravenous rapid injection, followed by 10-15IU/kg body weight per hour by intravenous infusion. Under normal circumstances, patients undergoing long-term hemodialysis use of this product have few times to adjust the dose, and therefore few times to detect anti-XA concentration. The dose administered usually keeps the plasma concentration within the range of 0.5-1.0IU anti-XA/mL.
3. Patients with acute renal failure are at high risk of bleeding: patients receiving intravenous rapid injection of 5-10IU/kg body weight, followed by intravenous infusion of 4-5IU/kg body weight per hour for acute hemodialysis have a short treatment interval and should be comprehensively monitored against -XA. Plasma concentration should be kept within the range of 0.2-0.4IU anti-XA/mL.
Unstable coronary artery disease, such as unstable angina pectoris and non-Q-wave myocardial infarction. 120IU/kg subcutaneously twice a day. The maximum dose is 10000IU/12 hours. Treatment for at least 6 days may be extended if the doctor deems it necessary. A low dose of acetylsalicylic acid is recommended.
5. Prevention of surgically related thrombosis:
(1) major surgery with risk of thromboembolic complications: 1 to 2 hours before surgery, subcutaneous injection of 2500IU every morning after surgery until the patient can be active, generally 5-7 days or longer.
(2) Major surgery and orthopedic surgery with other risk factors: 5000IU hypodermic injection at night before surgery and 5000IU hypodermic injection at night after surgery. Treatment should continue until the patient is able to move, usually 5-7 days or longer. In addition, 2500IU can be injected subcutaneously at 1-2 hours before surgery and 8-12 hours after surgery. Then get a subcutaneous injection of 5000IU every morning.